Phase 3 Clinical Trials With Primary Completion Dates in September 2020

This is a list of Phase 3 trials with primary completion dates in September 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ABEO Abeona Therapeutics Inc. 2020-09-01 Phase 3 NCT04227106 Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
ABSCF AB Science S.A. 2020-09-01 Phase 3 NCT03766295 Masitinib Plus Gemcitabine in Pancreatic Cancer
ALDX Aldeyra Therapeutics, Inc. 2020-09-01 Phase 3 NCT04207736 The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
AXSM Axsome Therapeutics, Inc. 2020-09-01 Phase 3 NCT04068051 Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine
CATB Catabasis Pharmaceuticals, Inc. 2020-09-01 Phase 3 NCT03703882 Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
CDTX Cidara Therapeutics, Inc. 2020-09-01 Phase 3 NCT03667690 Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
HGEN Humanigen, Inc. 2020-09-01 Phase 3 NCT04351152 Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
JAZZ Jazz Pharmaceuticals plc 2020-09-01 Phase 3 NCT03533114 A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
MEDD Medical Imaging Corp. 2020-09-01 Phase 3 NCT04261777 Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
ODT Odonate Therapeutics, Inc. 2020-09-01 Phase 3 NCT03326674 Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
QURE uniQure N.V. 2020-09-01 Phase 3 NCT03569891 HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
RDY Dr. Reddy's Laboratories Limited 2020-09-01 Phase 3 NCT03976102 Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (FLINTER)
RIGL Rigel Pharmaceuticals, Inc. 2020-09-01 Phase 3 NCT03764618 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
TBPH Theravance Biopharma, Inc. 2020-09-01 Phase 3 NCT03750552 Clinical Effect of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure
TORC resTORbio, Inc. 2020-09-01 Phase 3 NCT04409327 Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
ZEAL Zealand Pharma A/S 2020-09-01 Phase 3 NCT03777176 Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism